DK3526244T3 - Peptider afledt af propeptidet ntsr3 og deres anvendelse ved behandling af depression - Google Patents

Peptider afledt af propeptidet ntsr3 og deres anvendelse ved behandling af depression Download PDF

Info

Publication number
DK3526244T3
DK3526244T3 DK17794365.1T DK17794365T DK3526244T3 DK 3526244 T3 DK3526244 T3 DK 3526244T3 DK 17794365 T DK17794365 T DK 17794365T DK 3526244 T3 DK3526244 T3 DK 3526244T3
Authority
DK
Denmark
Prior art keywords
ntsr3
propeptide
depression
treatment
peptides derived
Prior art date
Application number
DK17794365.1T
Other languages
English (en)
Inventor
Jean Mazella
Marc Borsotto
Catherine Heurteaux
Sébastien Moreno
Mariel Pietri
Alaeddine Djillani
Original Assignee
Centre Nat Rech Scient
Univ Cote D'azur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1754127A external-priority patent/FR3057266B1/fr
Application filed by Centre Nat Rech Scient, Univ Cote D'azur filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of DK3526244T3 publication Critical patent/DK3526244T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
DK17794365.1T 2016-10-11 2017-10-11 Peptider afledt af propeptidet ntsr3 og deres anvendelse ved behandling af depression DK3526244T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR1659781A FR3057267A1 (fr) 2016-10-11 2016-10-11 Procede de diagnostic/determination de l'efficacite de traitement de la depression
FR1752162A FR3057268B1 (fr) 2016-10-11 2017-03-16 Procede de diagnostic/determination de l'efficacite de traitement de la depression
FR1754127A FR3057266B1 (fr) 2016-10-11 2017-05-11 Peptides derives du propeptide ntsr3 et leur utilisation dans le traitement de la depression
PCT/FR2017/052788 WO2018069641A1 (fr) 2016-10-11 2017-10-11 Peptides dérivés du propeptide ntsr3 et leur utilisation dans le traitement de la dépression

Publications (1)

Publication Number Publication Date
DK3526244T3 true DK3526244T3 (da) 2023-12-11

Family

ID=59297081

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17794365.1T DK3526244T3 (da) 2016-10-11 2017-10-11 Peptider afledt af propeptidet ntsr3 og deres anvendelse ved behandling af depression

Country Status (11)

Country Link
US (2) US20200190172A1 (da)
EP (2) EP3526244B1 (da)
JP (2) JP2019534259A (da)
CA (2) CA3039273A1 (da)
DK (1) DK3526244T3 (da)
ES (1) ES2965080T3 (da)
FI (1) FI3526244T3 (da)
FR (3) FR3057267A1 (da)
HR (1) HRP20231567T1 (da)
PT (1) PT3526244T (da)
WO (2) WO2018069641A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114544821B (zh) * 2020-11-24 2023-10-24 重庆医科大学 检测血浆中磷脂酰乙醇胺（36:4）的试剂在制备抑郁症检测试剂盒中的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE545429T1 (de) 2002-12-20 2012-03-15 Lundbeck & Co As H Modulation der neurotrophinaktivität;screeningsverfahren
EP2077278A1 (fr) * 2007-12-21 2009-07-08 Centre National de la Recherche Scientifique (CNRS) Peptide dérivé du récepteur 3 de la neurotensine et utilisation dans le traitemement de maladies psychiatriques
US20120322060A1 (en) * 2011-04-13 2012-12-20 Centre National De Le Recherche Scientifique - Cnrs - Diagnosis and monitoring treatment of psychiatric diseases with spadin and related methods
WO2015110915A2 (en) * 2014-01-27 2015-07-30 Medincell Retro-inverso analogs of spadin display increased antidepressant effects
JP2017508144A (ja) * 2014-02-12 2017-03-23 ハー・ルンドベック・アクチエゼルスカベット 感情／気分障害のバイオマーカーとしてのソルチリンの使用

Also Published As

Publication number Publication date
WO2018069640A3 (fr) 2018-06-07
WO2018069641A1 (fr) 2018-04-19
ES2965080T3 (es) 2024-04-11
US20200190172A1 (en) 2020-06-18
US11220527B2 (en) 2022-01-11
FR3057267A1 (fr) 2018-04-13
CA3040054A1 (fr) 2018-04-19
EP3526244B1 (fr) 2023-09-06
HRP20231567T1 (hr) 2024-03-15
EP3526244A1 (fr) 2019-08-21
JP2019534259A (ja) 2019-11-28
FR3068697A1 (fr) 2019-01-11
FI3526244T3 (en) 2023-12-11
FR3057268A1 (fr) 2018-04-13
US20190270771A1 (en) 2019-09-05
WO2018069640A2 (fr) 2018-04-19
EP3526243A2 (fr) 2019-08-21
PT3526244T (pt) 2023-12-11
CA3039273A1 (fr) 2018-04-19
JP2020502995A (ja) 2020-01-30
JP7034151B2 (ja) 2022-03-11
FR3057268B1 (fr) 2021-06-04

Similar Documents

Publication Publication Date Title
DK3678668T3 (da) ENPP1-inhibitorer og deres anvendelse til behandling af kræft
DK3096798T3 (da) Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem
DK3612517T3 (da) Bicykliske forbindelser og deres anvendelse ved behandling af cancer
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3472183T3 (da) Variant adeno-associerede virus og fremgangsmåder til anvendelse
DK3400291T3 (da) Manipuleret virus
DK3581190T3 (da) Manipulerede naturlige dræberceller og anvendelser deraf
DK3402888T3 (da) Middel og fremgangsmåder til behandling af hbv
DK3149019T3 (da) Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme
DK3185854T3 (da) Injicerbare opslæmninger og fremgangsmåder til fremstilling og anvendelse af disse
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3350201T3 (da) Manipulerede fytaser og fremgangsmåder til anvendelse af samme
DK3185957T3 (da) Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
DK3201336T3 (da) Fremgangsmåder til ekstrahering og oprensning af ikke-denaturerede proteiner
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3455372T3 (da) Polynukleotidberigelse og -amplifikation ved anvendelse af argonautsystemer
DK3432899T3 (da) Anvendelse af probiotika ved behandling og/eller forebyggelse af psoriasis
DK3416957T3 (da) 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes
DK3099800T3 (da) Ekspression og oprensning af crm197 og beslægtede proteiner
DK3556383T3 (da) Plasminogen til anvendelse ved behandling af diabetes
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3197898T3 (da) Hidtil ukendte imidazopyridazinforbindelser og deres anvendelse
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3551189T3 (da) Alprazolam til anvendelse ved behandling af epilepsi